清得健納豆膠囊食品
清得健納豆膠囊食品 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.
Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0
The foreign register category does not determine the regulatory category of the product in France.
French and European references for recognised ingredients
- À vérifier
The composition lists additive E171 (titanium dioxide), removed from the list of additives allowed in food, supplements included: since 7 August 2022, a supplement containing it can no longer be placed on the market in the Union.
règlement (UE) 2022/63. Regulation (EU) 2022/63: titanium dioxide (E171) removed from the food additives allowed in the EU, retrieved 23 October 2026.
Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.
Published composition
| Published ingredient | Published text and quantity | Identified nutrient or substance |
|---|---|---|
| BACILLUS NATTO | BACILLUS NATTO | Not identified |
| RHODIOLA SACHALINENSIS EXTRACT | RHODIOLA SACHALINENSIS EXTRACT | Not identified |
| GRAPE SEED | GRAPE SEED | Not identified |
| MONASCUS PILOSUS | MONASCUS PILOSUS | Not identified |
| GINKGO BILOBA L. FRUIT | GINKGO BILOBA L. FRUIT | Not identified |
| COENZYME Q10 | COENZYME Q10 | Ubiquinone |
| GELATIN | GELATIN | Not identified |
| SODIUM LAURYL SULFATE | SODIUM LAURYL SULFATE | Not identified |
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | Not identified |
| GLYCEROL | GLYCEROL | Glycérol |
| PONCEAU 4R | PONCEAU 4R | Not identified |
The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.
Product record
- Registration number
- 1110612953
- Chinese name
- 清得健納豆膠囊食品
- English name
- CHEONG-NA CAPSULES
- Type
- Imported tablets and capsules
- Published status
- Status not provided in this export; the validity date is shown separately
- Licence holder
- 雄美有限公司
- Registration date
- 2023-01-05
- Published validity end
- 2028-01-05
Original register data
View published fields and their variants
- Product name
- 清得健納豆膠囊食品
- Active ingredients
- BACILLUS NATTO;;RHODIOLA SACHALINENSIS EXTRACT;;GRAPE SEED;;MONASCUS PILOSUS;;GINKGO BILOBA L. FRUIT;;COENZYME Q10;;GELATIN;;SODIUM LAURYL SULFATE;;TITANIUM DIOXIDE;;GLYCEROL;;PONCEAU 4R;;
- Valid until
- 1170105
- Registration number
- 1110612953
- Licence holder
- 雄美有限公司
- Registration date
- 1120105
- Published reference
- DHC0B106129530
- Published English name
- CHEONG-NA CAPSULES
Official source
View the official register, number 1110612953
Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0
Open Government Data License, version 1.0
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- COENZYME Q10
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.